2[1]Eide FE, Loweustein DH,Reichardt LF. Neurotrophins and their receptors:Current concepts and implication for neurologic disease [J]. Exp Neurol , 1993,121(2):200.
3[5]De Santis S, Pace A, Bove L. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor [ J ]. Clin Cancer Res,2000,6(1) :90 - 95.
4[10]Saleh M,Shenaq MD, Eric D, et al. Gene therapy for plastic and reconstructive surgery[J]. Clin Plast Surg, 1996,23(1) :157 - 171.
5[11]Apfel SC, Kesser JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy [J]. Neurology, 1998,51(3) :695 - 702.
6[12]Zochodne DW, Said G. Recombinat human nerve growth factor and diabetic polyneuropathy[ J ]. Neurology, 1998,51 ( 3 ): 662 -663.
7[13]Apfel SC, Schwartz S,Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: randomized controlled trial [ J ]. JAMA, 2000,284(17) :2215 - 2221.
8[14]McArthur JC, Yiannoutsos C, Simpson DM. A phase Ⅱ trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291 [J ]. Neurology,2000,54(5): 1080 - 1088.
9[15]Polydefkis M, Yiannoutsos CT, Cohen BA, et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy[ J ]. Neurology, 2002,58 ( 1 ): 115 - 119.
10Marchetti D, Denkins Y, Peiland J. Brain-metastatic melanoma: a neurotrophic perspective [ J ]. Pathology Oncology Research, 2003,9(3) :147-158.
